Immunoglobulin heavy variable 1-69-positive B-cell receptor (IGHV1-69+ BCR)

The IGHV1-69+ B-cell receptor (BCR) is a specific subset of the B-cell receptor complex defined by the utilization of the IGHV1-69 germline gene in the heavy chain variable region. It is highly significant in hemato-oncology as the most frequently expressed BCR in unmutated Chronic Lymphocytic Leukemia (CLL), where it is associated with aggressive disease progression and poor clinical outcomes [7, 17]. These receptors often exhibit "stereotyped" configurations and polyreactivity, recognizing both self-antigens and viral proteins, which may drive the constitutive signaling and expansion of malignant B-cell clones [9, 10]. Interestingly, IGHV1-69-encoded antibodies also form a crucial part of the human immune repertoire against pathogens like Influenza and Hepatitis C, frequently serving as the basis for broadly neutralizing antibodies [4, 5]. In therapy, the IGHV1-69+ BCR is targeted directly by experimental anti-idiotypic monoclonal antibodies such as HuG6 and peptide-based ligands like p1 to selectively deplete leukemic cells [7, 12]. Additionally, signaling from this receptor is managed clinically using Bruton's tyrosine kinase (BTK) inhibitors and other BCR pathway antagonists [8, 12].

Other names

VH1-69 B-cell receptorIGHV1-69-encoded B-cell receptor51p1-positive B-cell receptorStereotyped subset 1 B-cell receptorIGHV1-69+ BCR

Anti-idiotypic antibody-mediated cytotoxicity, Bruton tyrosine kinase (BTK) inhibition, B-cell receptor signaling blockade, and anti-CD20 mediated B-cell depletion.